Poland is slowly expanding beyond its position as a central European generics hub. More established companies are adding innovative medicine pipelines and a small number of biotechs are making international deals.

Alissa Healthcare and King Pharmaceuticals have admitted colluding over UK supplies of nortriptyline to keep prices up, following an investigation launched by the country’s CMA.

This week's round up includes CEO appointments by GSK, who has appointed Brian McNamara CEO of the company's consumer unit, Clinigen and The Grünenthal Group; and executive appointments by Sanofi, where Alan Main has joined as executive vice president consumer healthcare global business unit, Immune Design, Advaxis, Kite Pharma and Bavarian Nordic.

Chinese pharmaceutical giant Sinopharm’s subsidiary has finalized a licensing agreement with Israeli firm Oramed for China rights to an oral insulin capsule, paving the way for further changes in the country’s huge diabetes market. Hefei meanwhile is pushing ahead with plans to become China’s high-end insulin production base, helped by several cross-border collaborations.